Poster
Dato-DXd
ELCC 2026 | March 25-28, 2026
Lung Cancer
Full device assessment of trophoblastic cell surface antigen 2 (TROP2) normalized membrane ratio (NMR) in non-small cell lung carcinoma (NSCLC) using a computational pathology algorithm in real-world laboratories
Fernando Lopez-Rios
Poster
Dato-DXd
ELCC 2026 | March 25-28, 2026
Lung Cancer
Identification of DXd sensitivity biomarkers and osimertinib-enhanced datopotamab deruxtecan (Dato-DXd) internalization as potential mechanisms for enhanced activity of Dato-DXd in preclinical models of EGFR-mutant non-small cell lung cancer
Matthew Sung
Poster
T-DXd
ELCC 2026 | March 25-28, 2026
Lung Cancer
Phase 1b study of first-line trastuzumab deruxtecan plus volrustomig in patients with HER2-overexpressing non-small cell lung cancer: DESTINY-Lung03 part 5
David Planchard
Oral
Valemetostat
ELCC 2026 | March 25-28, 2026
Lung Cancer
Safety of valemetostat plus pembrolizumab in advanced or metastatic 1L NSCLC without actionable genomic alterations expressing PD-L1 with TPS ≥ 50%: Interim results from the phase 1b trial
Sarah W. Gordon
Poster
Dato-DXd
ELCC 2026 | March 25-28, 2026
Lung Cancer
TROP2 normalised membrane ratio (NMR) assessed by quantitative continuous scoring (QCS): Association with clinical outcomes with datopotamab deruxtecan (Dato-DXd) ± osimertinib in EGFR-mutated (EGFRm) NSCLC
Jacob Sands
Poster
Dato-DXd
ELCC 2026 | March 25-28, 2026
Lung Cancer
TROPION-Lung17: A randomised phase 3 study of datopotamab deruxtecan (Dato-DXd) vs docetaxel in patients with previously-treated TROP2 NMR positive advanced/metastatic non-squamous non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGA)
Jacob Sands